Dhiraj Gambhire
Overview
Explore the profile of Dhiraj Gambhire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
1062
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andre F, Park Y, Kim S, Takano T, Im S, Borges G, et al.
Lancet
. 2023 Apr;
401(10390):1773-1785.
PMID: 37086745
Background: In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine; a population...
2.
Modi S, Gambhire D, Cameron D
N Engl J Med
. 2022 Sep;
387(12):1145-1146.
PMID: 36130006
No abstract available.
3.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al.
N Engl J Med
. 2022 Jun;
387(1):9-20.
PMID: 35665782
Background: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available...
4.
Tolcher A, Sznol M, Hu-Lieskovan S, Papadopoulos K, Patnaik A, Rasco D, et al.
Clin Cancer Res
. 2017 Jun;
23(18):5349-5357.
PMID: 28634283
This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137 in combination with...
5.
Subbiah V, Chuang H, Gambhire D, Kairemo K
Diagnostics (Basel)
. 2017 Feb;
7(1).
PMID: 28212290
In this era of precision oncology, there has been an exponential growth in the armamentarium of genomically targeted therapies and immunotherapies. Evaluating early responses to precision therapy is essential for...
6.
Gaba R, Gambhire D, Uy N, Gonzalez E, Iyer D, Hampe C, et al.
J Diabetes Complications
. 2015 Jun;
29(7):918-22.
PMID: 26071380
Objective: Unprovoked "A-β+" Ketosis-Prone Diabetes (KPD), a unique diabetic syndrome of adult-onset, obesity and proneness to ketoacidosis, is associated with rapid recovery of β cell function and insulin-independence. Whereas most...
7.
Pai V, Paneerselvam A, Mukhopadhyay S, Bhansali A, Kamath D, Shankar V, et al.
J Diabetes Sci Technol
. 2014 May;
8(1):132-141.
PMID: 24876549
Dual PPARα/γ can improve both metabolic effects and minimized the side effects caused by either PPARα or PPARγ agonist. The PRESS V study was aimed to evaluate the safety, tolerability,...